Windtree Therapeutics
WINT
WINT was delisted on the 20th of August, 2025.
8 hedge funds and large institutions have $1.76M invested in Windtree Therapeutics in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
11% less funds holding
Funds holding: 9 → 8 (-1)
35% less capital invested
Capital invested by funds: $2.72M → $1.76M (-$967K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$157K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$66K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$52.5K |
| 4 |
Two Sigma Advisers
New York
|
-$52.5K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$21K |
WINT Hedge Fund Activity: Q1 2022 in Review
8 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q1 2022, worth a combined $1.76M — down 35% from $2.72M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of WINT and 0 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, cutting an estimated $157K.
- 8 institutional investors held Windtree Therapeutics (WINT) as of Q1 2022, down from 9 in Q4 2021.
- Funds reported $1.76M of Windtree Therapeutics stock for Q1 2022, down 35% quarter-over-quarter.
- 0 funds opened new Windtree Therapeutics positions in Q1 2022 and 1 closed out, a net change of -1 holder.
- The largest Windtree Therapeutics seller in Q1 2022 was Vanguard Group, an estimated $157K sold.
Based on aggregated 13F filings for Q1 2022.